Anti-Mouse CD123 50 ug
- Known as:
- Antibody toMouse CD123 50 ug
- Catalog number:
- 12-1231-81
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse CD123 50
Related genes to: Anti-Mouse CD123 50 ug
- Gene:
- IL3RA NIH gene
- Name:
- interleukin 3 receptor subunit alpha
- Previous symbol:
- -
- Synonyms:
- CD123
- Chromosome:
- Xp22.3 and Yp13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-10-28
- Date modifiied:
- 2015-12-11
Related products to: Anti-Mouse CD123 50 ug
Related articles to: Anti-Mouse CD123 50 ug
- Chimeric antigen receptor (CAR) T cells require an extracellular targeting domain for antigen specificity, typically an scFv. VHH antibodies are emerging as alternative CAR binding regions due to their reduced size, improved stability, and CDR3 loop architecture. Herein, we generated and compared VHH and scFv antibodies targeting CD123, via immunized phage display libraries, selecting ten antibody pairs based on comparable domain targeting and kinetic profiles (K range M 10-10). The VHH antibody fragments showed improved stability (Tm Δ7.85°C), reduced aggregation, and a favorable surface charge. CARs incorporating a VHH demonstrated higher IL2 and IFNγ secretion than scFv-derived CARs during in vitro analysis and substantially enhanced survival and decreased tumor burden in a xenograft murine model of acute myeloid leukemia (AML). This comprehensive comparison of the two most adopted antibody classes provides a rationale for the selection of VHH as preferred CAR binding domains. - Source: PubMed
Publication date: 2026/06/10
Kinna AlexanderDatta PreetaBughda ReyisaParekh FarhaanRobson MathewJha RamWu PhillipScott IanHogben ElizabethAmin OliverWeng-Kit Cheung GordonHazelton WarrenAkbar ZulaikhaLamb KatarinaMacken EmilyAllen ChrisPanovska SofiHogan LisaEl-Kholy MohamedShrestha ReeveshPopplewell JonathanKokalaki EvangeliaSillibourne JamesThomas SimonOnuoha ShimobiFerrari MathieuPule Martin - Rosacea, discoid lupus erythematosus (DLE), and polymorphous light eruption (PLE) can present with overlapping clinical and histopathological features. This study aimed to compare the immunohistochemical and histopathological findings of these lesions and to evaluate the contribution of immunohistochemistry to the differential diagnosis. - Source: PubMed
Publication date: 2026/04/27
Aydin OzgeKilinc Fahriye - There are many studies about the correlation between Bataknese and schizophrenia patients, one of the most common ethnic in Indonesia. Cytokine and its’ receptor disorder is one of the scope of immunology research in schizophrenia. Interleukin 3 (IL-3) is an important cytokine with various biologic roles in immune response. We would like to determine the association between the polymorphism of IL3RA gene with negative symptoms in Bataknese schizophrenia patients. - Source: PubMed
Publication date: 2026/02/27
Asrika Asrul DikaEffendy ElmeidaMahmud Amin MustafaCamellia VitaYamamoto Zulham - Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by profound molecular heterogeneity and high relapse rates, posing significant clinical challenges. Programmed cell death (PCD), encompassing diverse regulated modalities such as apoptosis, necroptosis, and ferroptosis, plays a key role in leukemogenesis and therapeutic response; however, a comprehensive prognostic framework integrating multi-modal PCD pathways in AML remains elusive. In this study, we performed a systematic transcriptomic analysis of 1624 genes associated with 13 distinct PCD forms. A novel computational pipeline combining a variational autoencoder (VAE) for dimensionality reduction and a multilayer perceptron (MLP) for classification was employed to identify robust PCD-related biomarkers, interpreted via SHapley Additive exPlanations (SHAP) analysis. This approach identified 48 candidate genes with discriminative potential between AML and normal bone marrow. Unsupervised consensus clustering based on these genes delineated two molecular subtypes exhibiting divergent clinical outcomes and immune microenvironment profiles. The subtype demonstrated an immunosuppressive phenotype, characterized by enriched regulatory T cells, M2 macrophages, and elevated expression of inhibitory immune checkpoints, correlating with inferior survival. We developed an 8-gene prognostic signature (, , , , , , and ) that effectively categorized patients into high- and low-risk groups with notable survival differences, validated across independent cohorts. A prognostic nomogram combining the risk score, age, and cytogenetic risk enhanced the prediction accuracy for overall survival. Our study presents an integrative model that connects multi-modal PCD pathways to AML prognosis, offering a new molecular subtyping system and a clinically applicable risk assessment tool for improved prognostication and personalized treatment strategies. - Source: PubMed
Publication date: 2026/03/27
Zhang ChunlongNi HaisenZhao ZiyiZhao Ning - Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by dismal clinical outcomes. CD123, theαchain of the IL-3 receptor, is aberrantly overexpressed on AML blasts, representing a promising target for targeted immunotherapy. However, the clinical utility of CD123-targeted immunotherapies has been severely hampered by treatment-associated toxicities that disrupt normal hematopoietic homeostasis. In contrast, γδ T cells, endowed with the unique capacity to recognize antigens in a major histocompatibility complex (MHC)-independent manner, exert minimal cytotoxicity against normal tissues. Upon specific activation and engagement with CD3/CD123 bispecific antibodies (BsAbs), these cells potently and selectively target CD123⁺ AML blasts while mitigating CRS risk, offering a safer and more effective AML therapeutic strategy. - Source: PubMed
Publication date: 2026/03/27
Zhao YanyunSun YangSun HuiyanCui ChengchengZhang XiaoxuWang WeiWang Lisheng